
On-X® Aortic Heart Valve
Aortic Heart Valve
A Valve for Life.




Product Highlights
- The only aortic mechanical valve with FDA, Health Canada, and CE Mark approval for Low INR of 1.5 – 2.0.1
- Clinically proven to be safer with less anticoagulation resulting in >60% reduction in bleeding and no increase in thromboembolism (TE).1-2
- Unique material and design provide optimal mean gradients compared with other bileaflet and bioprosthetic aortic valves at ≥1 year. 1,3-7
Product Overview
1. 90° Leaflets
Promote laminar flow1

On-X Heart Valves
90° Opening

All Other Bileaflet Valves
< 90° Opening
2. Pure Pyrolytic Carbon
Designed to reduce thrombogenicity1-2

Pure Pyrolytic Carbon2

Silicon-Alloyed Pyrolytic Carbon2
3. Complete Annulus Support
Flared inlet organizes flow & prevents pannus1

Complete Annulus Support

Incomplete Annulus Support


CYLINDRICAL END
Used to find the correct fit for aortic valve sizes 19-25mm.

REPLICA END
Used after sizing to assure fit of the valve without obstruction of the coronary arteries for aortic valve sizes 19-25mm.

CONICAL ENDS
Used to find correct fit and assure intra-annular positioning for aortic valve sizes 27/29mm and 31/33mm.

Working with Artivion’s team was the best experience I’ve had in my medical career. Not only that, but the On-X is a revolutionary innovation in heart valve technology.

Working with Artivion’s team was the best experience I’ve had in my medical career. Not only that, but the On-X is a revolutionary innovation in heart valve technology.

Working with Artivion’s team was the best experience I’ve had in my medical career. Not only that, but the On-X is a revolutionary innovation in heart valve technology.

Working with Artivion’s team was the best experience I’ve had in my medical career. Not only that, but the On-X is a revolutionary innovation in heart valve technology.
Clinical Evidence
ON-X AORTIC HEART VALVE: 50% CLOSER TO A NORMAL INR1
Patients with an INR of 1.5–2.0 had a >60% reduction in bleeding events and no increase in TE compared to patients with an INR of 2.0–3.0.* All other bileaflet aortic valve anticoagulation should be managed at an INR of 2.0–3.0.2

OPTIMAL HEMODYNAMICS
The On-X Aortic Valve provides optimal mean gradients compared with other bileaflet and bioprosthetic aortic valves at ≥1 year. 3-10,¥

SURVIVAL AFTER VALVE REPLACEMENT: BIOLOGIC VS. MECHANICAL
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
VALVE DURABILITY: REOPERATION VS. VALVE PERFORMANCE
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Featured Videos
This is a text description area that provides a brief summary of the video or multi-video content to provide context for engagement.
Additional Resources
Explore additional resources for On-X below. For further information or to contact a sales associate in your area, contact us.
ORDERING INFORMATION
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
MRI INFORMATION
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
PATIENT INFORMATION SITE
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Product Highlights
- On-X Prosthetic Heart Valve Instructions for Use.
- Puskas JD, et al. J Am Coll Cardiol 2018;71:2717-26.
- St. Jude Medical Physician’s Manual Mechanical Heart Valve.
- CarboMedics Prosthetic Heart Valve Instructions for Use.
- Medtronic Open Pivot Heart Valve Instructions for Use.
- Edwards Life Sciences Carpentier-Edwards PERIMOUNT Magna Ease Pericardial Aortic Bioprosthesis Model 3300TFX Instructions for Use.
- Medtronic Mosaic Porcine Bioprosthesis with Cinch Advanced Implant System Instructions for Use.
Product Design Features
- On-X Prosthetic Heart Valve Instructions for Use.
- LaGrange L et al., Compatibility of carbon and blood. Hegyeli RJ, Editor, Proceedings, Artificial Heart Program Conference, Washington, DC, June 9-13, 1969, 47-58.
Clinical Evidence
- Nishimura et al., 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2017;135:e1159–e1195.
- Normal INR is considered 1. WHO Expert Committee on Biological Standardization, 33rd Report, World Health Organization, 1983.
- http://apps.who.int/iris/bitstream/10665/39217/1/WHO_TRS_687.pdf, downloaded on 06/29/2016.5. Data on file. 6. Levine M et al., Monitoring of international normalized ratios: comparison of community nurses with family physicians. Can Fam Physician 2012;58:e465-71.
- On-X Prosthetic Heart Valve Instructions for Use.
- St. Jude Medical Physician’s Manual Mechanical Heart Valve.
- CarboMedics Prosthetic Heart Valve Instructions for Use.
- Medtronic Open Pivot Heart Valve Instructions for Use.
- Edwards Life Sciences Carpentier-Edwards PERIMOUNT Magna Ease Pericardial Aortic Bioprosthesis Model 3300TFX Instructions for Use.
- Medtronic Mosaic Porcine Bioprosthesis with Cinch Advanced Implant System Instructions for Use.
- ** Medtronic Open Pivot AP and AP360 (formerly ATS): 16 = 19, 18 = 21, 20 = 23, 22 = 25, 24 = 27, 26 = 29.
- ¥ Postoperative data. Note: Mean gradients for On-X Aortic Valve 27 and 29 were combined.